Immunotherapies, PARP Inhibitors Show Promise in Early Stage, Triple-Negative Breast Cancers
March 23rd 2023Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.
Read More
Expert: Bi-Enabled Technology in Radiation Oncology Is Shortening Time From Diagnosis to Treatment
March 9th 2023Through automated tools related to scheduling, prior authorization, and radiation planning tasks, there are efforts to shorten the time from diagnosis to treatment to improve patient outcomes.
Watch
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination Rates
March 9th 2023Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Read More
Guidelines Recommend SGLT2 Inhibitors for Nearly All Patients With Heart Failure, Kidney Disease
March 6th 2023The 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines recommend SGLT2 inhibitors for nearly all patients in cardiovascular practice.
Read More
Newer Cardiovascular Drugs Are Being Incorporated Into Practice, but Access Remains a Challenge
March 6th 2023Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.
Read More
ACC 2023 Session Highlights Need for Pharmacists in Cardio-Oncology Care Teams
March 6th 2023Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.
Read More